Sign In
Last checked at 
30 Jun 2009 12:00
Tuesday 30 June 2009
Allergy Therapeutics plc
("Allergy Therapeutics" or "the Company")
Result of General Meeting
Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, is pleased to announce that at the General Meeting of the Company held today all of the resolutions were duly passed by shareholders. The proxy voting figures for the resolutions will be available in due course on the Company's website at http://www.allergytherapeutics.com/AGM.aspx
An application has been made for the 181,631,937 placing, subscription and offer shares of 0.1p each to be admitted to trading on AIM. It is expected that admission will become effective and dealings will commence at 08.00 am on 1 July 2009.
Total Voting Rights Following Admission
After Admission of the placing, subscription and offer shares, the Company's issued voting share capital will consist of 263,998,551 ordinary shares of 0.1p each.
For further information
|
Allergy Therapeutics |
+44 (0) 1903 845 820 |
|
Keith Carter, Chief Executive |
|
|
www.allergytherapeutics.com |
|
|
Nomura Code Securities |
+44 (0) 207 776 1200 |
|
Juliet Thompson/ Clare Terlouw |
|
|
Financial Dynamics |
+44 (0) 207 831 3113 |
|
Ben Brewerton/ Susan Quigley |
Follow the stocks
